CO4230094A1 - Composiciones - Google Patents

Composiciones

Info

Publication number
CO4230094A1
CO4230094A1 CO94021615A CO94021615A CO4230094A1 CO 4230094 A1 CO4230094 A1 CO 4230094A1 CO 94021615 A CO94021615 A CO 94021615A CO 94021615 A CO94021615 A CO 94021615A CO 4230094 A1 CO4230094 A1 CO 4230094A1
Authority
CO
Colombia
Prior art keywords
methyl
excipients
pharmaceutically acceptable
carbazol
ona
Prior art date
Application number
CO94021615A
Other languages
English (en)
Inventor
Isabelle Thielemans
Richard Isabelle
Original Assignee
Glaxo Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Sa filed Critical Glaxo Lab Sa
Publication of CO4230094A1 publication Critical patent/CO4230094A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/02Suppositories; Bougies; Bases therefor; Ovules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

REIVINDICACION NUMERO UNA COMPOSICION FARMACEUTICA, PARA ADMINISTRACION RECTAL, CARACTERIZADA PORQUE COMPREDNE 1,2,3,9-TE- TRAHIDRO-9-METIL-3- ((2-METIL-1H-IMIDAZOL-1-IL)- METIL)4H-CARBAZOL-4-ONA, EN FORMA DE SU PASE LIBRE O DE UN SOLVATO FARMACEUTICAMENTE ACEPTABLE DE LA MISMA, COMO INGREDIENTE ACTIVO, JUNTO CON UNO O MAS PORTADORES O EXCIPIENTES FARMACEUTICAMENTE A- CEPTABLES". REIVINDICACION NUMERO UN METODO PARA EL TRATAMIENTO DE UN MAMIFERO, IN- CLUYENDO EL HOMBRE, QUE SUFRE O ES SUSCEPTIBLE DE UNA CONDICION MEDIADA A TRAVES DE LA ACCION DE LA 5-HIDROXITRIPTAMINA, EN LOS RECEPTORES 5-HT3, EL CUAL METODO COMPRENDE LA ADMINISTRACION RECTAL DE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE LA 1,2,3,9-TETRAHIDRO-9-METIL-3-2((2-METIL-1H-IMIDA- ZOL-1-IL)-METIL)-4H-CARBAZOL-4-ONA, EN FORMA DE SU BASE LIBRE O DE UN SOLVATO FARMACEUTICAMENTE ACEP- TABLE DE LA MISMA, COMO INGREDIENTE ACTIVO, JUNTO CON UNO O MAS PORTADORES O EXCIPIENTES FARMACEUTI- CAMENTE ACEPTABLES.
CO94021615A 1993-05-25 1994-05-23 Composiciones CO4230094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939310756A GB9310756D0 (en) 1993-05-25 1993-05-25 Compositions

Publications (1)

Publication Number Publication Date
CO4230094A1 true CO4230094A1 (es) 1995-10-19

Family

ID=10736089

Family Applications (1)

Application Number Title Priority Date Filing Date
CO94021615A CO4230094A1 (es) 1993-05-25 1994-05-23 Composiciones

Country Status (38)

Country Link
US (1) US5741806A (es)
EP (1) EP0700290B1 (es)
JP (1) JP2965703B2 (es)
KR (1) KR100297212B1 (es)
CN (1) CN1106194C (es)
AP (1) AP544A (es)
AT (1) ATE183643T1 (es)
AU (1) AU680918B2 (es)
BE (1) BE1007158A3 (es)
BR (1) BR1100046A (es)
CA (1) CA2162919C (es)
CO (1) CO4230094A1 (es)
CY (1) CY2411B1 (es)
CZ (1) CZ291041B6 (es)
DE (1) DE69420266T2 (es)
DK (1) DK0700290T3 (es)
EC (1) ECSP941088A (es)
ES (1) ES2136198T3 (es)
FR (1) FR2705569B1 (es)
GB (2) GB9310756D0 (es)
GR (1) GR3031669T3 (es)
HR (2) HRP940315B1 (es)
HU (1) HU227121B1 (es)
IE (1) IE80632B1 (es)
IL (1) IL109749A (es)
IS (1) IS1868B (es)
IT (1) IT1272990B (es)
MY (1) MY111445A (es)
NO (1) NO306448B1 (es)
NZ (1) NZ267415A (es)
PE (1) PE13395A1 (es)
PL (1) PL175578B1 (es)
RU (1) RU2132684C1 (es)
SA (1) SA94150003B1 (es)
SG (1) SG48119A1 (es)
SI (1) SI0700290T1 (es)
WO (1) WO1994027599A1 (es)
ZA (1) ZA943593B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535135A (en) * 1998-06-15 2006-04-28 Sepracor Inc Use of optically pure (+)-norcisapride for treating bulimia and other disorders
AU764474B2 (en) * 1998-06-15 2003-08-21 Sepracor, Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1464333A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (-) norcisapride in the treatment of apnea, bulimia, and other disorders
EP1468685A3 (en) * 1998-06-15 2004-12-15 Sepracor Inc. Use of optically pure (+)-norcisapride for treating apnea, bulimia and other disorders
US6362202B1 (en) 1999-03-02 2002-03-26 Sepracor Inc. Methods and compositions using (−) norcisapride in combination with proton pump inhibitors or H2 receptor antagonists
US6353005B1 (en) 1999-03-02 2002-03-05 Sepracor, Inc. Method and compositions using (+) norcisapride in combination with proton pump inhibitors or H2 receptor antagonist
AU7931301A (en) * 2000-08-04 2002-02-18 Dmi Biosciences Inc Method of using diketopiperazines and composition containing them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
CH664152A5 (fr) * 1984-01-25 1988-02-15 Glaxo Group Ltd Derives de tetrahydrocarbazolones.
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5166145A (en) * 1990-09-10 1992-11-24 Alza Corporation Antiemetic therapy

Also Published As

Publication number Publication date
AU680918B2 (en) 1997-08-14
SA94150003B1 (ar) 2005-04-11
PE13395A1 (es) 1995-05-25
AP9400643A0 (en) 1994-07-31
DE69420266T2 (de) 1999-12-09
GB9409835D0 (en) 1994-07-06
IL109749A (en) 1999-03-12
IE940420A1 (en) 1994-11-30
FR2705569A1 (fr) 1994-12-02
HU227121B1 (en) 2010-07-28
NO954783D0 (no) 1995-11-24
GB2279008B (en) 1997-06-18
HRP940315B1 (en) 2000-12-31
DE69420266D1 (de) 1999-09-30
CA2162919A1 (en) 1994-12-08
BR1100046A (pt) 1999-11-23
HRP970315A2 (en) 1999-04-30
CZ308595A3 (en) 1996-06-12
DK0700290T3 (da) 2000-03-13
AU6970994A (en) 1994-12-20
EP0700290B1 (en) 1999-08-25
NO954783L (no) 1995-11-24
HRP940315A2 (en) 1996-08-31
SG48119A1 (en) 1998-04-17
SI0700290T1 (en) 1999-12-31
IT1272990B (it) 1997-07-01
ATE183643T1 (de) 1999-09-15
IE80632B1 (en) 1998-10-21
FR2705569B1 (fr) 1995-11-10
EP0700290A1 (en) 1996-03-13
PL311721A1 (en) 1996-03-04
HU9503375D0 (en) 1996-01-29
CN1106194C (zh) 2003-04-23
MY111445A (en) 2000-05-31
US5741806A (en) 1998-04-21
AP544A (en) 1996-10-11
IL109749A0 (en) 1994-08-26
CN1124454A (zh) 1996-06-12
PL175578B1 (pl) 1999-01-29
CA2162919C (en) 1999-07-20
RU2132684C1 (ru) 1999-07-10
IS4168A (is) 1994-11-26
GB2279008A (en) 1994-12-21
ZA943593B (en) 1995-02-13
NO306448B1 (no) 1999-11-08
KR100297212B1 (ko) 2001-10-24
ES2136198T3 (es) 1999-11-16
JPH08510457A (ja) 1996-11-05
ITRM940322A1 (it) 1995-11-24
WO1994027599A1 (en) 1994-12-08
GR3031669T3 (en) 2000-02-29
JP2965703B2 (ja) 1999-10-18
GB9310756D0 (en) 1993-07-14
HUT74867A (en) 1997-02-28
CZ291041B6 (cs) 2002-12-11
ECSP941088A (es) 1994-11-16
NZ267415A (en) 1997-10-24
CY2411B1 (en) 2004-11-12
ITRM940322A0 (it) 1994-05-24
BE1007158A3 (fr) 1995-04-11
IS1868B (is) 2003-05-02

Similar Documents

Publication Publication Date Title
AR002355A1 (es) Composiciones y metodos para administracion local de agentes farmaceuticamente activos.
CO5680428A2 (es) Antagonistas del receptor de trombina
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
ES2145774T3 (es) Derivados de adenosina que tienen actividad agonista en a2.
BR0215184A (pt) composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada
ES2150663T3 (es) Tratamiento de la incontinencia urinaria utilizando (s)-oxibutinina y (s)-desetiloxibutinina.
ES2174129T3 (es) Antagonistas de la hormona de liberacion de la gonadotropina.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
NL300385I1 (nl) Synergistic combinations comprising a renin inhibitor for cardiovascular diseases.
RS54390B1 (sr) Kombinovana vakcina protiv mycoplasma hyopneumoniae i svinjskog cirkovirusa
PA8496301A1 (es) Inhibidores de metaloproteasas.
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
GT199700095A (es) Derivados 6,5-heterobiciclicos sustituidos.
ES2088388T3 (es) Composiciones de macrolido para el tratamiento de trastornos de movilidad gastrointestinal.
CO5261519A1 (es) Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
ES2156287T3 (es) Derivados de difenilmetilen piperidina.
AR024998A1 (es) Nuevos retinoides para el tratamiento del enfisema
UY27208A1 (es) Una combinación que comprende combretastatina y agentes anticarcinógenos.
CO4230094A1 (es) Composiciones
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
AR005970A1 (es) Compuestos de benzotiofeno y formulaciones farmaceuticas que los contienen como agente activo
TR200200473T2 (tr) Rar selektif retinoid agonistleri.
ES2113533T3 (es) Composiciones farmaceuticas de alquilsulfonamidas agonistas de 5-ht1 para administracion rectal.
AR034142A1 (es) Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion